7 research outputs found
Chapter Natural Gas Catalytic Partial Oxidation: A Way to Syngas and Bulk Chemicals Production
No full textComputer modelling & simulatio
Natural Gas Catalytic Partial Oxidation: A Way to Syngas and Bulk Chemicals Production
No full textComputer modelling & simulatio
Selected Lectures of the 13th International Workshop on Neonatology; Cagliari (Italy); October 25th-28th, 2017
No full textSelected Lectures of the 13th International Workshop on Neonatology • The power of Epigenetics • Twins: identical but different • Cagliari (Italy) • October 25th-28th, 2017
LECT 1. ASPHYXIA IN THE THIRD MILLENNIUM: FROM VIRGINIA APGAR TO METABOLOMICS • O.D. Saugstad
LECT 2. INTRAPARTUM FETAL MONITORING: WHERE ARE WE NOW? • D. Ayres-de-Campos
LECT 3. THERAPEUTIC HYPOTHERMIA: REVISED INDICATIONS • E. Saliba
LECT 4. ANTIBIOTICS PRESCRIPTION IN NEONATAL INTENSIVE CARE UNIT • G. Dimitriou
LECT 5. CHORIOAMNIONITIS: FROM CLASSIC DATA TO METABOLOMICS • L. Pugni, C. Fattuoni, C. Pietrasanta, A. Ronchi, A. Noto, L. Barberini, F. Mosca, V. Fanos
LECT 6. FUNGAL INFECTIONS • A. Giannattasio, L. Capasso, T. Ferrara, S. Salomè, A. Umbaldo, R. Albachiara, F. Raimondi
LECT 7. METABOLOMICS IN SEPSIS: THE POWER OF PREDICTION • V. Fanos, R. Pintus, A. Noto, A. Dessì
LECT 8. PROBIOTICS IN OBSTETRICS and GYNAECOLOGY • G. Ettore, E. Palma, N. Recine, L. Ferrara, C. Ettore
LECT 9. LATE PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROME: LIGHTS AND SHADOWS • C. Dani
LECT 10. PRECISION VENTILATION IN NEWBORN • P.E. Tagliabue, M.L. Ventura, E. Zannin, R. Dellacà
LECT 11. PRECISION NON-INVASIVE VENTILATION IN NEWBORNS • C. Moretti, F. Midulla, C.S. Barbara, R. Nenna, L. Di Lucchio, C. Gizzi
LECT 12. BRONCHOPULMONARY DYSPLASIA: FROM NORTHWAY TO METABOLOMICS • D. Manus, V. Masile, M.C. Pintus, A. Dessì, V. Fanos
LECT 13. RESPIRATORY SYNCYTIAL VIRUS INFECTION: WHAT’S NEW? • M. Lanari, C. Biagi
LECT 14. EMERGENCY IN OBSTETRICS, WORLDWIDE • R. Baiocchi, K. Picucci, E. Bruni
LECT 15. NEONATOLOGY IN AFGHANISTAN • M. Testa
LECT 16. NEW PERSPECTIVES IN HUMAN MILK FORTIFIERS • E. Bertino, G.E. Moro, P. Tonetto, C. Peila, L. Occhi, E. Spada, G. Ansaldi, S. Deantoni, L. Cavallarin, M. Giribaldi, A. Coscia, A. Dessì, V. Fanos
LECT 17. GUT PERTURBATION AND PROBIOTICS IN NEONATOLOGY • G. Biasucci
LECT 18. NEAR INFRARED SPECTROSCOPY AND GUT FUNCTION IN PRETERM NEWBORNS • L. Corvaglia, S. Martini
LECT 19. ALLERGY TO COW’S MILK PROTEIN • M. De Filippo, A. Licari, G.L. Marseglia
LECT 20. GLOMERULAR NUMBER IN LBW BABIES: NOTE FOR THE FUTURE. THE FAULT IS NOT IN OUR STARS BUT MAY BE IN OUR EMBRYOS • G. Remuzzi
LECT 21. VACCINE-PREVENTABLE DISEASES • A. Villani, E. Bozzola, A.C. Vittucci, A. Grandin, C. Di Camillo, L. Lancella
LECT 22. WHAT IS NEW IN PATENT DUCTUS ARTERIOSUS TREATMENT? • F. Bardanzellu, P. Neroni, A. Dessì, M.A. Marcialis, V. Fanos
LECT 23. NEW PROSPECTS FOR PEDIATRIC RESPIRATORY MEDICINE FROM METABOLOMICS • M. Stocchero, G. Giordano, P. Pirillo, E. Priante, S. Carraro, E. Baraldi
LECT 24. NEW BIOMARKERS AND “OMICS” IN PREECLAMPSIA • M. Mussap, C. Ierace
LECT 25. MATERNAL MILK: IMMUNOMICS AND MICROBIOMICS • D.G. Peroni
LECT 26. NUTRIMETABOLOMICS OF MILK: COLOSTRUM AND MORE • A. Dessì, R. Pintus, F. Cesare Marincola, V. Fanos
LECT 27. AUTISM FROM CONVENTIONAL DIAGNOSIS TO METABOLOMICS: URINARY METABOLOMICS PROFILE IN A POPULATION OF CHILDREN WITH AUTISM SPECTRUM DISORDERS • P. Curatolo, A. Noto, M. Siracusano, A. Riccioni, L. Mazzone, L. Barberini, V. Fanos, C. Fattuoni
LECT 28. PLACENTAL BIOMARKERS • A.M. Paoletti, B. Piras, P. Abis, V. Corda, M. Neri, M.F. Marotto, M. Angiolucci, G.B. Melis, F. Coghe, V. Mais
LECT 29. BIOMARKERS IN NEONATAL SEPSIS • R. Örs
LECT 30. ACUTE KIDNEY INJURY IN NEWBORNS • C. Aygun
LECT 31. BIOMARKERS IN CARDIOLOGY • G. Mercuro, P.P. Bassareo
LECT 32. QUANTIFICATION IN NEONATAL URINE AND PROFICIENCY TESTING COMPARED TO NON-NMR METHODS • M. Spraul, H. Schäfer, C. Cannet, F. Fang
LECT 33. ENHANCING IMMUNE RESPONSES IN CHILDREN WITH RECURRENT RESPIRATORY INFECTIONS • G.V. Zuccotti, C. Mameli
LECT 34. OBSTETRICAL MANAGEMENT IN TWIN PREGNANCIES • E. Cosmi, L. Marin, S. Visentin
LECT 35. THE PATHOLOGIST AND TWINS • D. Fanni, C. Gerosa, G. Faa
LECT 36. TWINS: THE POWER OF EPIGENETICS • G. Corsello, A. Corsello
LECT 37. MANAGEMENT OF PERINATAL LOSS OF TWINS • M. Puddu, E. Melis, V. Fanos
LECT 38. NEUROPSYCHIATRIC PROBLEMS IN TWINS • M. Guarnieri, C. Ciampi
LECT 39. SELF-REPORTED AGGRESSIVE BEHAVIOR IN HUMANS AND BIOMARKERS: A FOCUS ON LIPIDS AND METHYLATION • F.A. Hagenbeek, J. van Dongen, C.K. Kluft, L. Ligthart, G. Willemsen, E.J.C. de Geus, M. Bartels, D.I. Boomsma
LECT 40. SOFT TISSUE TUMORS IN THE NEONATAL AND PEDIATRIC SETTING • R. Sciot
LECT 41. PLACENTAL SOFT TISSUE TUMORS • G. Faa, C. Rossi, D. Fanni, E. Di Felice, V. Fanos, C. Gerosa
LECT 42. DO OBSTETRICIANS REALLY KNOW PLACENTA? • S. Angioni
LECT 43. ULTRASOUND AND PLACENTA • G. Monni, A. Iuculano
LECT 44. MALE AND FEMALE PLACENTA: A REVOLUTION? • G. Faa, E. De Felice, C. Rossi, D. Fanni, V. Marinelli, V. Fanos, C. Gerosa
LECT 45. DO NEONATOLOGISTS REALLY KNOW PLACENTA? • S. Perrone, M.G. Alagna, G. Buonocore
LECT 46. S100B EXPRESSION IN PLACENTA • A. Faa, D. Fanni, C. Gerosa, G. Faa
LECT 47. ACUTE CHORIOAMNIONITIS AND NEONATAL OUTCOME • C. Gerosa, C. Rossi, E. Di Felice, M. Angiolucci, V. Fanos, G. Faa
LECT 48. METABOLOMICS AND PLACENTA • C. Fattuoni, L. Barberini
LECT 49. ARTIFICIAL PLACENTA • S. Dessole, G. Capobianco, M. Dessole, C. Pini, A. Gulotta
LECT 50. LOW DOSE MEDICINE: A NEW PHARMACOLOGICAL PARADIGM. FROM PRINCIPLES TO RESEARCH • S. Bernasconi, G. Bona
LECT 51. REASONABLE USE OF ANTIBIOTICS IN PEDIATRIC AGE: ALTERNATIVE THERAPIES OR CONCURRENT THERAPIES? • G. Trapani
LECT 52. NEONATAL SEIZURES: AN ITALIAN SURVEY ON CURRENT TREATMENT AND MONITORING PRACTICES • D. Pruna, R. Dilena, P. De Liso, M. Di Capua
LECT 53. A TAILORED CLINICAL APPROACH TO THE TREATMENT OF MONOSYMPTOMATIC NOCTURNAL ENURESIS • G. Masnata, V. Manca, C. Guzzetti, F. Esu
LECT 54. UNFORGETTABLE CASE REPORTS • F. Bardanzellu, M.E. Trudu, A. Atzei, G. Ottonello
LECT 55. HIPS SONOGRAPHY IN THE THIRD MILLENIUM • M. Crisafulli, F. Piu, P. Balloi, R. Pintus, A. Dessì
LECT 56. NEONATAL PHARMACOLOGY: WHAT’S THE NEWS? • L. Cuzzolin
LECT 57. AIR NEONATAL TRANSPORTS IN SARDINIA: FROM STORK WINGS TO AIRPLAIN’S • A. Atzei, M. Puddu, G. Ottonello, V. Fanos
LECT 58. MORE THAN 50 YEARS OF HOSPITAL FLIGHTS FOR THE ITALIAN AIR FORCE • Italian Air Force, 31st Wing, Captain D. Sgambati
LECT 59. NEONATAL TRANSPORT IN ITALY AND BEYOND • S. Rugolotto
LECT 60. A HEART OF... JERSEY • A. Brandi
LECT 61. THE ITALIAN REFORM CONCERNING CIVIL AND CRIMINAL LIABILITIES IN THE HEALTH FIELD • F. Tregnaghi
LECT 62. A MEDICO-LEGAL VIEW AT THE MEDICAL LIABILITY CONTEXT : LIGHTS AND SHADOWS OF THE ITALIAN “NEW LAW NUMBER 24/2017 GELLI-BIANCO” • F. Paribello, E. d’Aloja
LECT 63. WHAT LEGAL MEDICAL RESPONSIBILITY FOR THE NEONATOLOGIST? • C. Romagnoli
LECT 64. A NEW LAW ON PROFESSIONAL LIABILITY: BETWEEN UNSOLVED TANGLES AND ONGOING COMPLIANCE TO NEW RULES. THE ROLE OF SCIENTIFIC SOCIETIES • R. Agostiniani
LECT 65. THE ROLE OF SCIENTIFIC SOCIETIES WITHIN THE FRAMEWORK OF THE NEW ITALIAN LEGISLATION ON PROFESSIONAL LIABILITY • G. Di Mauro
LECT 66. THE NEW REALITY OF MEDICAL PROFESSIONAL RESPONSIBILITY IN ITALY • A. Canetto
LECT 67. MEDICAL PROFESSIONAL ACCOUNTABILITY: THE NEW REALITY IN ITALY. THE OPINION OF THE PEDIATRIC SURGEON • L. Mascia
LECT 68. A NEW APPROACH IS NEEDED FOR EFFECTIVE PREVENTION AND MANAGEMENT OF NEONATAL SKIN INJURIES • S. Tuccio, L. Guarinoni, L. Cirillo, L. Bruno, E. Duca, S. Zucchini, R. Memoli, D. Gerardini
LECT 69. NURSING PRIORITIES TO NEWBORNS WITH DIGESTIVE OSTOMIES • M. Zicchi, S. Porcu, M.G. Pizzarri, A.R. Tanca, M. Ubertazzi, M.G. Olzai, M.G. Clemente
LECT 70. INTEGRATING MICROBIOMICS AND METABOLOMICS DATA IN BEHAVIORAL COMPLEX TRAITS: A ROLE IN AGGRESSION? • M. Manchia, V. Fanos
LECT 71. AGGRESSIVENESS FROM FETUS TO ADULT: THE TWINS CASE • R. Pintus, A. Dessì, A. Noto, V. Fanos
LECT 72. DOHaD, NUTRITION AND BASIC RESEARCH • C. Mandò, I. Cetin
LECT 73. ENVIRONMENTAL FACTORS AND EPIGENETIC MECHANISMS • L. Migliore
LECT 74. PERINATAL PROGRAMMING AND BRAIN • V. Fanos, R. Pintus
LECT 75. ANESTHESIA ON THE DEVELOPING BRAIN OF THE FETUS AND INFANT: THE DARK SIDE OF THE COIN • G. Finco, P. Mura
LECT 76. EXPOSOMICS: ENVIRONMENT, EPIGENETIC FETAL PROGRAMMING AND PREVENTION OF CHRONIC PATHOLOGIES • E. Burgio, L. Migliore, I. Cetin, G. Faa, O. Forleo, F. Cesare Marincola, R. Pintus, A. Dessì, A. Noto, V. Fano
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)
No full textIntroduction: We evaluated the effectiveness, tolerability, and safety of eptinezumab in preventing high-frequency episodic migraine (HFEM) and chronic migraine (CM) over 24 weeks in real-world. We also assessed its impact during the first treatment week, in patients failing monoclonal antibodies targeting the calcitonin gene-related peptide (anti-CGRP mAbs), and the effects of dose escalation to 300 mg in patients requiring enhanced control. Methods: EMBRACE II is a multicenter (n = 22), prospective, 24-week, real-world study involving consecutive patients with HFEM or CM who had failed > 3 preventive treatments. Eptinezumab (100 mg, with the option for escalation to 300 mg at week 12) was administered quarterly. Primary endpoint: change in monthly migraine days (MMD), for HFEM or monthly headache days (MHD), for CM, between weeks 21-24 and baseline. Secondary endpoints: changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. Results: Of the 215 participants who had received ≥ 1 eptinezumab dose, 74 were treated for ≥ 24 weeks and considered for effectiveness analysis. Eptinezumab significantly (p < 0.001) reduced MMD/MHD (- 10.5), MAI (- 15.6), NRS (- 2.2), HIT-6 (- 9.9), MIDAS (- 48.7), and MIBS-4 (- 4.3). ≥ 50% responders were 69%, ≥ 75% responders 39.2%, and 100% responders 4.1%. Comparing the first week with the last baseline week, a significant reduction in migraine days was observed (- 3.7; p < 0.001). Significant improvements were seen in patients failing anti-CGRP mAbs (32.4%) and in those escalating to 300 mg (33.8%). Half of the subjects reported being "very much improved" or "much improved". The adverse events were infrequent (2.8%). Conclusions: This real-world study documents that 24-week eptinezumab treatment is rapidly effective and well tolerated in migraine patients with multiple therapeutic failures (including anti-CGRP mAbs). One-third of patients escalated to 300 mg at week 12, achieving further significant migraine-related disability reduction
Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy
No full textMembranoproliferative glomerulonephritis (MPGN) is currently stratified into complement C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). However, classification is subject to continued debate.
Here, we applied hierarchical clustering to a much larger cohort of patients with C3G/ICMPGN (295 individuals), extensively characterized for genetic and autoimmune complement abnormalities, with the goal of unraveling specific disease patterns. We also designed a user-friendly web application that with input of data at diagnosis could make cluster classification clinically applicable.
Five clusters with unique phenotypic and complement profiles were identified. Cluster 1 and 2 patients showed systemic complement activation until C5. Consistently, C5 nephritic factor and anti-factor B antibodies were prevalent in these clusters. Cluster 2 was distinguished from cluster 1 for classical pathway activation markers in biopsy. Cluster 3 showed C3-restricted systemic complement activation associated with the prevalence of C3 nephritic factor. Cluster 4 and 5 patients shared a normal complement profile and intense glomerular C3 staining, consistent with solid-phase complement activation, but cluster 5 distinguished for the higher prevalence of genetic abnormalities. Cluster 4 patients had the highest incidence of kidney failure during follow-up, while cluster 1 had the best kidney prognosis. However, clusters 1 and 2 showed a high risk of post-transplant recurrence. Through our web application, we could visually compare the predicted profile of new patients with those of patients included in clustering analysis and assign these patients to different clusters. The cluster-based classification allows etiologic diagnosis of C3G/IC-MPGN and had better prognostic value than current approaches.
Our proposed strategy may possibly guide anti-complement treatment.
Copyright © 2025. Published by Elsevier Inc
El significado de la prosopopeya de las Leyes en el "Critón" de Platon
No full textThe purpose of this paper is to make a study of the personification of the Laws (nomoi) of Athens in Platoʼs Crito from the philosophy of law. The prosopopoeia of the Laws is a central aspect to understand the play, as they start an imaginary dialogue with Socrates in which various philosophical arguments are exposed to base the authority of the polis. In order to identify the argumentative value of this resource in the play, firstly I will analyze the meaning of nomos in the Athens of the 5th century BC, and secondly the nature of the Laws in the general context of the dialogue. It aims to show the importance of the Laws to explain Socratesʼ decision to drink the hemlock.El objeto de este trabajo es realizar un estudio iusfilosófico sobre la aparición de las Leyes (nómoi) personificadas de Atenas en el Critón de Platón. La prosopopeya de las Leyes resulta ser un aspecto central para poder comprender la obra, ya que éstas entablan un diálogo imaginario con Sócrates en el cual instalan diversos argumentos filosóficos para fundamentar la autoridad de la pólis. A los fines de identificar el valor argumentativo de este recurso en la obra, analizaré el significado del nómos en la Atenas del siglo V a. C. y la naturaleza de las Leyes en el contexto general del diálogo. Se busca demostrar la importancia que tienen aquéllas para explicar la decisión de Sócrates de beber la cicuta
